Home › Atherosclerosis › NCT07839936

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of VERVE-102, a One-Time Dose Gene Editing Medicine, in Adults With or at High Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Who Require Additional Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering

Who can join

Ages 18 to 70 · All sexes

Inclusion Criteria:

* Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD

Exclusion Criteria:

* History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)
* Chronic liver disease
* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe

About the study

The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.

What is being tested

• VERVE-102 (drug)
• Placebo (drug)

Sponsor: Verve Therapeutics, Inc. · Participants: 175 · Started: Sep 24, 2026

Contact the study team

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · Phone: 317-615-4559

Official record on ClinicalTrials.gov — NCT07839936

Locations in the U.S.

Conditions

• Atherosclerosis
• Cardiovascular Disease
• Cholesterol
• Coronary Artery Disease
• Heart Attack
• Stroke

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.